KRAS and cancer: In contrast, KRAS(ON) inhibitors specifically target the active, GTP-bound KRAS to combat KRAS-driven cancers.71 Several KRAS(ON) inhibitors have been developed and tested in preclinical and clinical studies, including RMC-6236, RMC-4998, and RMC-7977.